Baird lowered the firm’s price target on Larimar Therapeutics (LRMR) to $10 from $13 and keeps an Outperform rating on the shares. Th efirm updated its model following Q4 results which showed the FDA is open to Skin FXN as a surogate endpoint with a BLA planned by year-end 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue